These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 26898815)
1. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815 [TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker. Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272 [TBL] [Abstract][Full Text] [Related]
3. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053 [TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer. Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432 [TBL] [Abstract][Full Text] [Related]
5. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300 [TBL] [Abstract][Full Text] [Related]
6. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116 [TBL] [Abstract][Full Text] [Related]
7. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944 [TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates. Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728 [TBL] [Abstract][Full Text] [Related]
9. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841 [TBL] [Abstract][Full Text] [Related]
10. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies. Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663 [TBL] [Abstract][Full Text] [Related]
12. Site-specific antibody-drug conjugation through glycoengineering. Zhou Q; Stefano JE; Manning C; Kyazike J; Chen B; Gianolio DA; Park A; Busch M; Bird J; Zheng X; Simonds-Mannes H; Kim J; Gregory RC; Miller RJ; Brondyk WH; Dhal PK; Pan CQ Bioconjug Chem; 2014 Mar; 25(3):510-20. PubMed ID: 24533768 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709 [TBL] [Abstract][Full Text] [Related]